Please find attached the minutes from the Extraordinary General Meeting (EGM) ofEXACT Therapeutics AS held on24 July 2020 . All resolutions were approved as proposed by the Board of Directors, including the 1:250 split of the company's shares and the appointment of EY as auditors. For further queries, please contact:Masha Stromme , Chair +47 93022509Stig Jarle Pettersen , CFO +47 90960336 EXACT-Tx is a clinical stage Anglo-Norwegian biotech company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com
Click here for more information
© Oslo Bors ASA, source